Vistin Pharma ASA: Second quarter and YTD 2025 financial results

Financial Performance - Vistin Pharma ASA reported second quarter revenue of MNOK 118, an increase from MNOK 106 in Q2 2024, driven by a 17% higher sales volume [1] - For the first half of 2025, revenue reached MNOK 233, up from MNOK 210 year-to-date in 2024, reflecting an 11% increase [1] - EBITDA for Q2 2025 was MNOK 30, compared to MNOK 27 in Q2 2024, marking an 11% increase [2] - Year-to-date EBITDA for the first half of 2025 was MNOK 60, up from MNOK 48 in the same period last year, representing a 27% increase [2] - The net profit for the first half of 2025 was MNOK 40.2, compared to MNOK 26.8 in the previous year [2] Shareholder Returns - A cash dividend of NOK 1.25 per share was distributed to shareholders in June 2025 [2]